Printer Friendly

Ireland : Medtronic Receives FDA Clearance of New Lower Profile HawkOne 6F Directional Atherectomy System.

Medtronic plc has received U.S. Food and Drug Administration (FDA) 510(k) clearance for the HawkOne(TM) Directional Atherectomy System in a new size for treating patients with peripheral artery disease (PAD). The HawkOne system is designed to remove plaque from the vessel wall and restore blood flow. The new HawkOne 6 French (6F) provides an effective and easy-to-use treatment option for patients with PAD both above and below the knee with a single device at a lower profile.

PAD is a serious, chronic condition that affects more than 200 million people worldwide1 and 12 million in the United States.2 In PAD, arteries in the legs become narrowed or blocked by plaque. This narrowing of the blood vessel can cause reduced blood flow to the leg, which can result in severe pain and limit physical mobility. When blocked arteries are below the knee, they are more likely to be calcified, and linked to lower treatment success.3 Patients with blocked arteries below the knee may also develop the most severe form of PAD, critical limb ischemia (CLI), which can result in non-healing leg ulcers and increased risk of amputation.4,5

"Considering the complex disease pattern seen in below-the-knee PAD, traditional treatment options such as placement of permanent stents or treatment with a balloon, may not be ideal for achieving long-term results. Directional atherectomy, on the other hand, is an established intervention that not only restores patency but also maximizes luminal gain while keeping future treatment options open," said Brian DeRubertis, M.D., associate professor of surgery at the David Geffen School of Medicine at UCLA. "The new, smaller HawkOne 6F device further adds to the versatility of this directional atherectomy system and enables us to treat a larger set of patients with more complex lesions, including patients with challenging calcified lesions."

The HawkOne 6F size is an advanced option to treat patients with multi-level PAD both above and below the knee, addressing lesions of various length, morphology, and location. Key benefits of the system include:

- Treating calcified lesions: The HawkOne system enables physicians to treat severe calcified lesions more efficiently with no increase in cut depth. The system can treat calcified lesions up to two times more effectively than the TurboHawk(TM)device.6

- Ease of use: The HawkOne system has a preloaded flush tool, which improves cleaning time by up to 55 percent when compared to the TurboHawk high efficiency cutter.7 The 6F size is also designed to simplify device selection and provide easy set-up with no capital equipment.

"The expansion of our HawkOne system provides physicians with more options to optimize directional atherectomy as an approach to PAD management, particularly for lesions below the knee," said Mark Pacyna, vice president and general manager of the Peripheral business, which is part of the Aortic & Peripheral Vascular division at Medtronic. "The HawkOne 6F clearance, as well as the recent approval of our 150mm length IN.PACT(TM) Admiral(TM) drug-coated balloon and clearance of the Trailblazer(TM) angled support catheter, reflects our commitment to a full portfolio of products to meet the needs of patients and physicians."

In collaboration with leading clinicians, researchers, and scientists worldwide, Medtronic offers the broadest range of innovative medical technology for the interventional and surgical treatment of cardiovascular disease and cardiac arrhythmias. The company strives to offer products and services that deliver clinical and economic value to healthcare consumers and providers around the world.

[c] 2016 Al Bawaba ( Provided by SyndiGate Media Inc. ( ).
COPYRIGHT 2016 SyndiGate Media Inc.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2016 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:Mena Report
Date:Oct 25, 2016
Previous Article:United States : PharmaCyte Biotech selects Dr. Manuel Hidalgo as Principal Investigator for Its Pancreatic Cancer Clinical Trial.
Next Article:Australia : Grants support Childrens Week events in WA.

Terms of use | Privacy policy | Copyright © 2019 Farlex, Inc. | Feedback | For webmasters